


Rec'd PCT/PTO 17 MAY 2005
PATENT COOPERATION TREATY

From the
 INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

A.A. THORNTON & CO.
 235 High Holborn
 London WC1V 7LE
 GRANDE BRETAGNE



PCT

NOTIFICATION OF TRANSMITTAL OF
 THE INTERNATIONAL PRELIMINARY
 EXAMINATION REPORT
 (PCT Rule 71.1)

Date of mailing
 (day/month/year) 21.02.2005

Applicant's or agent's file reference
 CPW/20933

IMPORTANT NOTIFICATION

International application No.
 PCT/GB 03/04981

International filing date (day/month/year)
 18.11.2003

Priority date (day/month/year)
 18.11.2002

Applicant
 CIPLA LTD et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the International
 preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2
 NL-2280 HV Rijswijk - Pays Bas
 Tel. +31 70 340 - 2040 Tx: 31 651 epo nl
 Fax: +31 70 340 - 3016

Authorized Officer

Bröcker-Tazelaar, G
 Tel. +31 70 340-2103



Rec'd PCT/PTO 17 MAY 2005

02074053580

16/ -1

PATENT COOPERATION TREATY

PCT 10/535187



INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference CPW/20933	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/GB 03/04981	International filing date (day/month/year) 18.11.2003	Priority date (day/month/year) 18.11.2002
International Patent Classification (IPC) or both national classification and IPC C07K5/062		
Applicant CIPLA LTD et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.
☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

I	<input checked="" type="checkbox"/>	Basis of the opinion
II	<input type="checkbox"/>	Priority
III	<input checked="" type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/>	Lack of unity of invention
V	<input checked="" type="checkbox"/>	Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input type="checkbox"/>	Certain documents cited
VII	<input type="checkbox"/>	Certain defects in the international application
VIII	<input type="checkbox"/>	Certain observations on the international application

Date of submission of the demand 26.05.2004	Date of completion of this report 21.02.2005
Name and mailing address of the International preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer Schmidt, Harald Telephone No. +31 70 340-4023 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB 03/04981

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-12 as originally filed

Claims, Numbers

1-25 as originally filed

Drawings, Sheets

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**International application No. **PCT/GB 03/04981**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).
- (Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*
6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- ☐ the entire international application,
 - ☒ claims Nos. 25 as to IA
- because:
- ☒ the said international application, or the said claims Nos. 25 relate to the following subject matter which does not require an international preliminary examination (specify):
- see separate sheet**
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 - ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 - ☐ no international search report has been established for the said claims Nos.
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the Standard.
 - ☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-15
	No: Claims	16-25
Inventive step (IS)	Yes: Claims	1-15
	No: Claims	16-25
Industrial applicability (IA)	Yes: Claims	1-24
	No: Claims	

2. Citations and explanations

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB 03/04981

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB 03/04981

Re Item III**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claim 25 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(I) PCT).

Re Item V**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: US 4914214

Novelty

The document D1 discloses a process for the preparation of perindopril and its t-butamine salt, wherein ethyl acetate and perindopril are mixed with t-butylamine (see esp. column 9, Stage 3D).

Although it is not explicitly mentioned in D1, it has to be assumed that said perindopril t-butylamine is at least partially (mono)hydrated, since example 5 of the current specification teaches that suspension of perindopril t-butylamine in ethyl acetate leads to its monohydrate form.

Furthermore, the subject-matter of claim 16 encompasses a pharmaceutically acceptable salt of perindopril in its non-hydrated form.

It is also mentioned that perindopril and its t-butylamine salt inhibit ACE and may be used as pharmaceuticals (see column 1).

Therefore, subject-matter of claims 16 to 25 does not meet the requirements of Article 33(2) PCT.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB 03/04981

Inventive step

The document D1 is considered to represent the closest prior art for the subject-matter of claims 1 to 15 and discloses a process for the preparation of perindopril t-butylamine from a protected precursor, wherein the deprotection step is followed by addition of t-butylamine to yield the t-butylamine salt of perindopril.

The subject-matter of claims 1 to 15 of the present application differs in that the deprotection is carried out in the presence of a base, preferably t-butylamine, without first deprotecting the carboxylic group of the heterocyclic ring, and thereby forming a pharmaceutically acceptable salt of perindopril.

The problem to be solved may therefore be considered as the provision of an improved process for the preparation of a pharmaceutically acceptable salt of perindopril, such as perindopril t-butylamine.

The solution resides in that the deprotection is carried out in the presence of a base which forms the pharmaceutically acceptable salt.

Such a solution is not obvious to the skilled person, since it cannot be expected without inventive skill that the process of claims 1 to 15 results in a reduction of undesirable impurities such as diketopiperazine analogues.

Hence, the subject-matter of claims 1 to 15 fulfils the requirements of Article 33(3) PCT.

Industrial applicability

The subject-matter of claims 1-24 meets the criteria of Article 33(4) PCT.

For the assessment of the present claim 25 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.